O. M. Afanasyeva

O. M. Afanasyeva

Auto-generated profile, based on publicly available information

O. M. Afanasyeva

Federal State Budget Institution of Science « Mechnikov Research Institute of Vaccines and Sera

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
OKO. M. Kukina
O. M. Kukina
IGI. M. Gruber
I. M. Gruber
NAN. K. Akhmatova
N. K. Akhmatova
OZO. V. Zhigunova
O. V. Zhigunova
EKE. A. Kurbatova
E. A. Kurbatova
NYN. E. Yastrebova
N. E. Yastrebova
Исследование иммунобиологических свойств поверхностных белоксодержащих антигенов Streptococcus pneumoniae серотипа 6B

13 March 2021 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
IGI. M. Gruber
I. M. Gruber
OKO. M. Kukina
O. M. Kukina
НЕН. Б. Егорова
Н. Б. Егорова
OZO. V. Zhigunova
O. V. Zhigunova
Relevance. The worldwide use of pneumococcal vaccines, in particular conjugated vaccines (PCV), has led to a significant reduction in the incidence of invasive pneumococcal diseases in both vaccinated children and unvaccinated people of all ages. However, "non-vaccine" serotypes and capsule-free (non-typed) strains have become the main causes of pneumococcal disease, as with carriage, with an increase in antibiotic resistance. This requires new approaches in the development of vaccines that can lead to serotype-independent protection, especially in children, the elderly and immunocompromised people. The pneumococcal vaccine should protect against a wide range of serotypes, induce mucosal and systemic immunity, and reduce primary nasal colonization, as well as invasive forms. Aim. The review is devoted to the analysis of experimental development of innovative vaccines based on protective protein antigens (PPV), including in combination with capsular polysaccharides, using adjuvants or antigen delivery systems, as well as inactivated whole cell preparations (WCV) and live attenuated vaccines. Particular attention is paid to the methods of mucosal immunization, taking into account the tropism of pneumococcus in relation to the mucous membranes of the upper and lower respiratory tract. Conclusion. At this stage, the most developed and promising are drugs based on bacterial lysates (PWCV) and protective protein antigens (PspA, dPly), as well as these antigens mixed with adjuvants, and, possibly, with some etiologically most significant capsular polysaccharides.

3 May 2025 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
OAO. M. Afanasyeva
O. M. Afanasyeva
IGI. M. Gruber
I. M. Gruber
DVD. S. Vorobyev
D. S. Vorobyev
OZO. V. Zhigunova
O. V. Zhigunova
MDM. N. Dmitrieva
M. N. Dmitrieva
Relevance. Mitis group streptococci (SMG) include 9 species of streptococci most frequently isolated from patients, including Streptococcus oralis and Streptococcus pneumoniae. The study of SMG shows not only differences but also overlaps in the genes encoding pathogenicity factors of S. pneumoniae and S. oralis. Earlier it was shown that antigens from S. pneumoniae serotype 6B induced cross-protective effect against virulent strains of S. pneumoniae. It was found that the experimental surface protein-containing fraction with molecular weight 30-100 kDa (PCF) from S. oralis has protective activity, stimulates in mice indicators of innate and adaptive immunity.Objective: to carry out a comparative analysis of pathogenicity factors of S. oralis and S. pneumoniae strains and protective activity of surface protein-containing antigens isolated from them.Materials and methods. The strains of S. oralis and S. pneumoniae serotype 6B Nos. 3353 and 1121 of different virulence were used. Experimental protein-containing antigens, in particular, PCF, were prepared from these strains. The protective activity of the obtained PCFs was evaluated in active protection experiments during intraperitoneal immunization and infection of BALB/c mice. Mass spectrometric study of PCF was carried out using UniProtKB database, taxon S. pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4.) Statistical processing of the results was carried out using parametric and nonparametric methods of comparison (p<0.05).Results and discussion. PCF from S. oralis has cross-species protective activity against virulent strains of S. pneumoniae of different serotypes, while PCF from S. pneumoniae strain 6B No. 3353 protects only against a virulent strain of the homologous serotype. Comparative analysis of genes encoding pathogenicity factors revealed differences: only in S. oralis genes encoding the synthesis of proteins promoting adhesion and biofilm formation (SspA, GtfD RlrA), and in S. pneumoniae strains - pore-forming toxin (Ply) and choline-binding protein (LytA) were identified. In the proteomic analysis of S. oralis and S. pneumoniae 6B No. 3353 PCFs, out of 673 identified proteins, 57 common proteins of most interest and 21 and 35 unique proteins, respectively, were selected for each PCF: in S. oralis PCFs, adhesion proteins were identified, as well as proteins related to metabolic systems and mediating the development of the infection process, while in S. pneumoniae PCFs, adhesion proteins were predominant those indirectly involved in the development of the infectious process, while the S. pneumoniae PCF is dominated by proteins related to the main pathogenicity factors.Conclusions. The surface protein-containing fraction 30 -100 kDa (PCF) isolated from a weakly virulent strain of S. oralis, belonging to the Mitis group streptococci, has interspecies protective activity against strains of closely related species - S. pneumoniae of different serotypes. PCF is capable of both preventing adhesion and colonization of pneumococcus and possibly playing the role of a natural adjuvant. In addition, it may be of interest to determine the protective effect of this antigen against other closely related SMG representatives. Both different and common genes encoding the synthesis of the main pneumococcal pathogenicity factors were identified in the strains, and unique proteins for each of them were determined by proteomic analysis of PCF.

14 March 2020 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
OKO. M. Kukina
O. M. Kukina
IGI. M. Gruber
I. M. Gruber
NANelli Kimovna Akhmatova
Nelli Kimovna Akhmatova
EKE. A. Kurbatova
E. A. Kurbatova
OZO. V. Zhigunova
O. V. Zhigunova
GBG. V. Beloshitsky
G. V. Beloshitsky
Серотипнезависимая протективная активность экспериментальных белоксодержащих препаратов Streptococcus pneumoniae , полученных из свежевыделенных и музейных штаммов

23 April 2019 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
IGI. M. Gruber
I. M. Gruber
NEN. B. Egorova
N. B. Egorova
EAE. A. Astashkina
E. A. Astashkina
NAN. K. Akhmatova
N. K. Akhmatova
EKE. A. Kurbatova
E. A. Kurbatova
OKO. M. Kukina
O. M. Kukina
Aim. Comparative study of immunobiological properties of cell wall surface antigens and extracellular protein-containing antigens of Staphylococcus aureus. Materials and methods. Preparations: surface antigens of the cell wall (peptidoglycan, teichoic acids, protein antigens) of the strains of S. aureus containing in the staphylococcal vaccine «Staphylovac» (SV) and extracellular protein-containing antigens of S. aureus (EPCA). The parameters of innate immunity were evaluated by the effect of preparations on the immunophenotype of mononuclear leukocytes (ML) of the spleen of mice, expression of Toll-like receptors (using flow cytometry), phagocytic activity of macrophages of peritoneal exudate of mice after the introduction of SV and EPCA; the protective activity of preparations was studied in experiments of active protection of BALB/c mice. Results. To isolate EPCA, we used the virulent strain of S. aureus №6, and for obtaining surface antigens of the cell wall, 4 strains were selected, the most immunogenic of which was the low virulent strain of S. aureus №1991. Both preparations increased the number of TLR2 and MHC II expressing cells; CV administration caused an increase in the number of cells with CD25 marker, reflecting the early activation of immunocompetent cells, and EPCA immunization — led to a shorter expression of this marker. On the other hand, an increased number of CD19 positive cells were detected for a longer period of time during EPCA immunization. The longest activation of phagocytosis under the action of SV was established. High protective activity of bo-th types of the studied preparations was noted. Conclusion. The antigens of the cell wall and extracellular protein-containing experimental drugs possessed comparable immunological properties, however, the surface antigens to a greater extent activate innate immunity, and extracellular — adaptive immunity.

3 December 2021 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
DVD. S. Vorobyev
D. S. Vorobyev
MTM. M. Tokarskaya
M. M. Tokarskaya
SBS. A. Baranovskaya
S. A. Baranovskaya
ESE. A. Stefutushkina
E. A. Stefutushkina
OAO. M. Afanasyeva
O. M. Afanasyeva
NMNatalia Mikhailova
Natalia Mikhailova
Introduction. Pneumococcal diseases remain relevant for the whole world. On the one hand, this is due to the high prevalence of pneumococcus and the other hand, the growth of antibiotic-resistant strains and the constant change of clinically significant serotypes of the pathogen.The aim of the research was to study of the protective activity of a mixture of pneumococcal antigens.Material and methods. we used preparations of a capsular polysaccharide (CPS) obtained from Streptococcus pneumoniae serotype 3; protein-containing fraction (PCF) obtained from an aqueous extract of cells of S. pneumoniae serotype 6B; recombinant pneumolysin (rPly). Mice were immunized intraperitoneally twice with an interval of 14 days with mixtures of bacterial antigens: CPS + PCF; CPS + rPly; PCF + rPly. To assess the protective activity of the studied drugs after double immunization animals were infected intraperitoneally with S. pneumoniae serotype 3. To study the effect of mixtures of bacterial preparations on the infectious process in the lungs immunized mice were infected with S. pneumoniae serotype 3. The humoral immune response was studied with IgG using the method of ELISA.Results. The CPS + rPly mixture protected mice from intraperitoneal infection with S. pneumoniae serotype 3 regardless of the infecting dose. Immunization with CPS + PCF or CPS + rPly mixtures influenced a significant decrease the number of seeded bacterial cells from lungs during the entire observation period (72 h) compared to the control. Administration of mixtures of bacterial antigens of CPS + PCF, CPS + rPly or PCF + rPly to animals led to a significant increase of the level of antibodies to all antigens, however, the highest levels of IgG were determined to PCF and rPly.Conclusion. The results obtained suggest that different antigenic drugs in mixtures affect different mechanisms of immunity activation.